Literature DB >> 9308789

Comparison between testosterone oenanthate-induced azoospermia and oligozoospermia in a male contraceptive study. IV. Suppression of endogenous testicular and adrenal androgens.

R A Anderson1, A M Wallace, A T Kicman, F C Wu.   

Abstract

Administration of supraphysiological doses of testosterone to normal men causes inhibition of spermatogenesis, but while most become azoospermic, 30-55% maintain a low rate of spermatogenesis. We have investigated whether there are differences in endogenous androgen production, of testicular and adrenal origin, which may be related to the degree of suppression of spermatogenesis. Thirty-three healthy Caucasian men were given weekly i.m. injections of 200 mg testosterone oenanthate (TE), 18 became azoospermic, while 15 remained oligozoospermic. Urinary excretion of epitestosterone, a specific testicular product, was reduced to <10% of pretreatment values, with no differences between the groups. Similar results were obtained for other markers of testicular steroidogenesis. Urinary and plasma adrenal androgens were also reduced during TE treatment: a statistically significant decrease in both (P < 0.001 and P < 0.05 respectively) was seen in the azoospermic but not oligozoospermic responders. These results suggest that testicular steroidogenesis is decreased to <10% by the administration of supraphysiological doses of exogenous testosterone. Differences in the degree of ongoing steroidogenesis in the testis do not appear to account for incomplete suppression of spermatogenesis, thus differences in androgen metabolism may underlie this heterogeneous response. A small but significant reduction in secretion of adrenal androgens was also detectable, the relevance of which is unclear.

Entities:  

Keywords:  Androgens; Biology; Clinical Research; Clinical Trials; Contraception; Contraceptive Agents, Male--administraction and dosage; Contraceptive Agents--administraction and dosage; Developed Countries; Endocrine System; Europe; Examinations And Diagnoses; Family Planning; Hormones; Laboratory Examinations And Diagnoses; Laboratory Procedures; Northern Europe; Physiology; Reproduction; Research Methodology; Research Report; Sperm Count; Spermatogenesis; Spermatogenesis Blocking Agents--administraction and dosage; Testosterone; United Kingdom

Mesh:

Substances:

Year:  1997        PMID: 9308789     DOI: 10.1093/humrep/12.8.1657

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

Review 1.  Hormone-Based Treatments in Subfertile Males.

Authors:  Darshan P Patel; Jason C Chandrapal; James M Hotaling
Journal:  Curr Urol Rep       Date:  2016-08       Impact factor: 3.092

2.  Dehydroepiandrosterone secretion in healthy older men and women: effects of testosterone and growth hormone administration in older men.

Authors:  Ranganath Muniyappa; Kelli A Wong; Howard L Baldwin; John D Sorkin; Michael L Johnson; Shalender Bhasin; S Mitchell Harman; Marc R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2006-08-22       Impact factor: 5.958

Review 3.  Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic-androgenic steroids (AAS).

Authors:  Ankit Desai; Musaab Yassin; Axel Cayetano; Tharu Tharakan; Channa N Jayasena; Suks Minhas
Journal:  Ther Adv Urol       Date:  2022-06-26

4.  Complete sperm suppression in rats with dienogest plus testosterone undecanoate is facilitated through apoptosis in testicular cells.

Authors:  Rekha Meena; Man Mohan Misro; Debidas Ghosh
Journal:  Reprod Sci       Date:  2012-11-30       Impact factor: 3.060

Review 5.  Current medical management of endocrine-related male infertility.

Authors:  Joshua D Ring; Aye A Lwin; Tobias S Köhler
Journal:  Asian J Androl       Date:  2016 May-Jun       Impact factor: 3.285

Review 6.  Exogenous testosterone: a preventable cause of male infertility.

Authors:  Lindsey E Crosnoe; Ethan Grober; Dana Ohl; Edward D Kim
Journal:  Transl Androl Urol       Date:  2013-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.